COMP <GO>
COLL vs JNJ // EV/EBITDA & P/E VALUATION
Collegium Pharmaceutical Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: COLL 4
— JNJ 7
▲ EV/EBITDA & P/E VALUATION LEADER: COLL
LAST: $24.03 (+3.44%) • MKT CAP: $782.3M
valuation
3.0x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COLL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.30% | 67.90% | -8.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 25.50% | +59.50 | COLL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 3.0x | 18.5x | -15.50 | COLL | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 23.00% | 34.70% | -11.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 28.50% | -20.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 23.60% | 6.00% | +17.60 | COLL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.27 | 5.59 | -4.32 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 62.1 | -5.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.4x | 23.0x | -12.60 | COLL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $782.3M | $662.49B | -$661.71B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COLL REV | JNJ REV | COLL GROSS % | JNJ GROSS % | COLL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $780.6M | $94.19B | 59.3% | 67.9% | $327.6M | $19.70B |
| FY 2024 | $631.4M | $88.82B | 59.8% | 69.1% | $203.3M | $19.84B |
| FY 2023 | $566.8M | $85.16B | — | — | $274.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
JNJ // BETA 1.08